Cephalon To Co-Market Vivitrex With Alkermes Through $500 Mil. Deal

The alcohol dependence therapy, which could be approved in September, will initially target patients already on pharmaceutical treatment. Cephalon will pay Alkermes $160 mil. upfront and could pay an additional $110 mil. if the agent is approved, on top of other milestone payments and profit sharing arrangements.